Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.

William P AccomandoAliz R RaoDaniel J HoganAaron M NewmanAki Nakao Ash A Alizadeh Maximillian DiehnOscar R DiagoDawn GammonAli HaghighiHarry E GruberDouglas J JollyDerek Ostertag

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

These results support an immune-related mechanism of action for Toca 511 and Toca FC, and suggest that molecular and immunologic signatures are related to clinical benefit from treatment.

Keyphrases

genome wide
gene expression
single molecule
dna methylation
drug induced